Patents Assigned to Amgen
  • CXCR3 ANTAGONISTS
    Publication number: 20110034487
    Abstract: Compounds, compositions and methods that are useful in the treatment of inflammatory and immune conditions and diseases are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of a chemokine receptor. The subject methods are useful for the treatment of inflammatory and immunoregulatory disorders and diseases, such as multiple sclerosis, rheumatoid arthritis, transplant rejection and type I diabetes.
    Type: Application
    Filed: January 21, 2009
    Publication date: February 10, 2011
    Applicant: AMGEN INC.
    Inventors: Xiaoqi Chen, Kirk Henne, Julio C. Medina
  • Tumor Endothelial Marker 5-alpha Molecules and Uses Thereof
    Publication number: 20110033472
    Abstract: The present invention provides Tumor Endothelial Marker 5? (TEM5?) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TEM5? polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, or prevention of diseases, disorders, and conditions associated with TEM5? polypeptides.
    Type: Application
    Filed: August 9, 2010
    Publication date: February 10, 2011
    Applicant: AMGEN INC.
    Inventor: Todd Juan
  • Methods for identifying functional antibodies
    Patent number: 7884054
    Abstract: The invention provides methods for screening multimeric antibodies produced by mammalian cells to find those that exhibit a biological function. The methods can be used to screen large numbers of antibodies, which may be cell surface, secreted, or intracellular antibodies. Antibodies can be screened to find those that bind antigen more avidly or those that compete with a ligand that binds to the antigen for binding. Any biological function that can be tested in vitro can be used to screen the antibodies. Nucleic acids encoding the antibodies that exhibit the biological function can be obtained in a number of ways.
    Type: Grant
    Filed: December 21, 2004
    Date of Patent: February 8, 2011
    Assignee: Amgen Inc.
    Inventors: Chen Zhou, Wenyan Shen, Francis H. Martin
  • Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptide and heterodimer thereof
    Patent number: 7883868
    Abstract: Novel ?10 polypeptides and heterodimers thereof, and nucleic acid molecules encoding the same are disclosed. The invention also provides vectors, host cells, selective binding agents, and methods for producing ?10 polypeptides and heterodimeric forms thereof, specifically ?2/?10. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with ?10 polypeptides and ?2/?10 heterodimers or their respective binding agents.
    Type: Grant
    Filed: February 27, 2008
    Date of Patent: February 8, 2011
    Assignee: Amgen Inc.
    Inventor: Christopher J. R. Paszty
  • ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)
    Publication number: 20110027287
    Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
    Type: Application
    Filed: October 12, 2010
    Publication date: February 3, 2011
    Applicant: AMGEN INC.
    Inventors: SIMON MARK JACKSON, NIGEL PELHAM CLINTON WALKER, DEREK EVAN PIPER, BEI SHAN, WENYAN SHEN, JOYCE CHI YEE CHAN, CHADWICK TERENCE KING, RANDAL ROBERT KETCHEM, CHRISTOPHER MEHLIN, TERESA ARAZAS CARABEO, QIONG CAO
  • Protein kinase modulators and method of use
    Patent number: 7880000
    Abstract: The present invention relates to chemical compounds having a general formula I wherein A, B, D, E, G, H1-5 and R1-4 are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of these kinases. For example, the compounds are capable of modulating kinase enzymes thereby influencing the process of angiogenesis and treating angiogenesis-related diseases and other poliferative disorders, including cancer and inflammation. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of protein kinases.
    Type: Grant
    Filed: May 9, 2005
    Date of Patent: February 1, 2011
    Assignee: Amgen Inc.
    Inventors: Stephanie D. Geuns-Meyer, Brian L. Hodous, Stuart C. Chaffee, Paul A. Tempest, Philip R. Olivieri, Rebecca E. Johnson, Brian K. Albrecht, Vinod F. Patel, Victor J. Cee, Joseph L. Kim, Steven Bellon, Xiaotian Zhu, Yuan Cheng, Ning Xi, Karina Romero, Hanh Nho Nguyen, Holly L. Deak
  • Antibodies to fibroblast growth factor-like polypeptides
    Patent number: 7879323
    Abstract: The present invention provides novel Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing FGF-like polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with FGF-like polypeptides.
    Type: Grant
    Filed: November 13, 2008
    Date of Patent: February 1, 2011
    Assignee: Amgen Inc.
    Inventors: Arlen Thomason, Benxian Liu
  • HOST CELLS COMPRISING ALPHA 1,2 MANNOSIDASE AND CULTURE METHODS THEREOF
    Publication number: 20110020811
    Abstract: Improved host cells and culture methods involving overexpression of MAN1C1 activity to improve protein production are provided.
    Type: Application
    Filed: May 21, 2010
    Publication date: January 27, 2011
    Applicant: Amgen Inc.
    Inventor: Christopher K. Crowell
  • IL-18 RECEPTOR ANTIGEN BINDING PROTEINS
    Publication number: 20110014201
    Abstract: Provided herein are IL-18 receptor antigen binding proteins and polynucleotides encoding the same. Expression vectors and host cells comprising the same for production of the antigen binding proteins are also provided. In addition, provided are compositions and methods for diagnosing and treating diseases mediated by IL-18 receptor.
    Type: Application
    Filed: July 24, 2008
    Publication date: January 20, 2011
    Applicant: AMGEN INC.
    Inventors: Dirk E. Smith, John E. Sims, Jeffrey T. McGrew, Marek Z. Kubin, Duncan Cochrane, Louise Conroy
  • Sclerostin-binding antibodies
    Patent number: 7872106
    Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.
    Type: Grant
    Filed: November 24, 2008
    Date of Patent: January 18, 2011
    Assignees: Amgen Inc., UCB Pharma S.A.
    Inventors: Christopher J. Paszty, Martyn K. Robinson, Kevin Graham, Alistair J. Henry, Kelly S. Warmington, John Latham, Hsieng S. Lu, Alastair Lawson, Andy Popplewell, Wenyan Shen, David G. Winkler, Aaron G. Winters
  • Benzisoxazole and isoxazolo-pyridine compounds and method of use
    Patent number: 7872128
    Abstract: The present invention comprises a new class of compounds capable of modulating the c-kit protein kinase and, accordingly, useful for treatment of c-kit mediated diseases including, without limitation, autoimmune disease, allergies, mastcytosis, mast cell related tumors and various fibrotic diseases. The compounds have a general Formula I wherein R1-5, X, Y and Z are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of c-kit mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.
    Type: Grant
    Filed: July 18, 2007
    Date of Patent: January 18, 2011
    Assignee: Amgen Inc.
    Inventors: Ning Chen, Essa Hu, Roxanne Kunz, Shannon Rumfelt, Andrew Tasker
  • Compositions and methods relating to anti IGF-1 receptor antibodies
    Patent number: 7871611
    Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.
    Type: Grant
    Filed: December 20, 2005
    Date of Patent: January 18, 2011
    Assignee: Amgen Inc.
    Inventors: Frank J. Calzone, Rajendra V. Deshpande, Mei-Mei Tsai
  • Beta-Secretase modulators and methods of use
    Patent number: 7872009
    Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, B, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.
    Type: Grant
    Filed: November 14, 2006
    Date of Patent: January 18, 2011
    Assignee: Amgen Inc.
    Inventors: Brian K. Albrecht, Denise Lyn Andersen, Michael Bartberger, James Brown, Ryan Brown, Stuart C. Chaffee, Yuan Cheng, Michael Croghan, Russell Graceffa, Scott Harried, Stephen Hitchcock, Randall Hungate, Ted Judd, Matthew Kaller, Charles Kreiman, Daniel La, Patricia Lopez, Craig Masse, Holger Monenschein, Thomas Nguyen, Thomas Nixey, Vinod F. Patel, Lewis Pennington, Matthew Weiss, Qiufen Xue, Bryant Yang, Wenge Zhong
  • IL-17 HETEROMERIC RECEPTOR COMPLEX
    Publication number: 20110008356
    Abstract: The present invention relates to Interleukin-17 ligand and receptor family members and the discovery that IL-17 receptor A and IL-17 receptor C form a heteromeric receptor complex that is biologically active.
    Type: Application
    Filed: June 13, 2008
    Publication date: January 13, 2011
    Applicant: AMGEN, INC.
    Inventors: Jacques J. Peschon, Joel Tocker, Dean Toy
  • POLYNUCLEOTIDES ENCODING IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS
    Publication number: 20110008841
    Abstract: The present invention relates to IL-17 receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, and the polynucleotide sequences encoding them, as well as host cells, expression vectors, and methods of making IL-17 receptor A antigen binding proteins.
    Type: Application
    Filed: June 25, 2010
    Publication date: January 13, 2011
    Applicant: Amgen Inc.
    Inventors: Joel TOCKER, Jacques J. Peschon, James F. Smothers
  • Anti-IgE antibodies
    Patent number: 7867494
    Abstract: The present invention relates to novel human antibodies specifically directed against human immunoglobulin E (anti-IgE). The present invention also relates to pharmaceutical compositions and methods for treating asthma, in particular allergic asthma, as well as other IgE-mediated disorders including allergic rhinitis and food allergies.
    Type: Grant
    Filed: April 1, 2008
    Date of Patent: January 11, 2011
    Assignees: Amgen Fremont Inc., Pfizer Inc.
    Inventors: Wai Liu, Mike Yeadon, Isabelle de Mendez, Alison Logan, Gerald F. Casperson, Arvind Rajpal, Mark A. Moffat, Wei Liao, Caroline Brown, Nurten Beyaz-Kavuncu, Judith Diaz-Collier, Sirid-Aimee Kellermann
  • Human anti-B7RP1 neutralizing antibodies
    Patent number: 7868140
    Abstract: This invention provides antibodies that interact with or bind to human B7 related protein-1 (B7RP1) and antibodies that bind to and neutralize the function of B7RP1 thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing B7RP1 function, and particularly for treating immune disorders (e.g., inappropriate immune response) by administering a pharmaceutically effective amount of anti-B7RP1 antibodies. Methods of detecting the amount of B7RP1 in a sample using anti-B7RP1 antibodies are also provided.
    Type: Grant
    Filed: July 18, 2006
    Date of Patent: January 11, 2011
    Assignees: Amgen Inc., Medarex Inc.
    Inventors: Gerald Siu, Wenyan Shen, Steven Kiyoshi Yoshinaga, Haichun Huang
  • Multi-cyclic compounds and method of use
    Patent number: 7868177
    Abstract: The present invention relates to chemical compounds having a general formula I wherein A, B, C1, C2, D, L1, L2 and R3-4 are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Tie-2 and Aurora kinase enzymes thereby influencing angiogenesis and the process of cell cycle and cell proliferation, respectively, to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of various protein kinases.
    Type: Grant
    Filed: February 21, 2007
    Date of Patent: January 11, 2011
    Assignee: Amgen Inc.
    Inventors: Victor J. Cee, Holly L. Deak, Stephanie D. Geuns-Meyer, Brian L. Hodous, Hanh Nho Nguyen, Philip R. Olivieri, Vinod F. Patel, Karina Romero
  • Fibroblast Growth Factor-Like Polypeptides
    Publication number: 20110003302
    Abstract: The present invention provides novel Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing FGF-like polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with FGF-like polypeptides.
    Type: Application
    Filed: June 1, 2010
    Publication date: January 6, 2011
    Applicant: AMGEN INC.
    Inventors: Arlen Read Thomason, Benxian Liu
  • Tumor Endothelial Marker 5-alpha Molecules and Uses Thereof
    Publication number: 20110003755
    Abstract: The present invention provides Tumor Endothelial Marker 5? (TEM5?) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TEM5? polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, or prevention of diseases, disorders, and conditions associated with TEM5? polypeptides.
    Type: Application
    Filed: March 22, 2010
    Publication date: January 6, 2011
    Applicant: AMGEN INC.
    Inventor: Todd Juan